MPPE1 and neoplasm: Combining BRAF inhibition therapy with Flt3-L and the TLR-3 agonist polyinosinic:polycytidylic acid (poly-I:C), to expand and activate intra-tumoral cDC1, leads to more effective anti-tumor therapy [41].